€7.2m · Other round · Healthtech · San Sebastián, Spain
San Sebastián-based Deneb Medical has secured a €7.2m equity investment from Spain's Society for Technological Transformation (SETT) to develop and bring its IZAR robotic spine-surgery platform to market. The SETT investment is part of a €14.7m public-private capital increase that also includes €5m from an unnamed US medical-device multinational and €2.5m from Kutxa Fundazioa through its Bidelagun programme.
The distinction matters: €7.2m is the investment captured by this Tech.eu event, while €14.7m is the total capital increase disclosed by Deneb and SETT. The company says the financing will support product development, commercial preparation and team growth while keeping its headquarters in San Sebastián.
One platform has to earn a place across the surgical workflow
IZAR is designed as a single station for planning, image-based patient registration, robot-guided pedicle-screw placement and laser tissue ablation. Deneb says the platform combines robotics, photonics and AI, and can work with screws from different manufacturers rather than tying hospitals to one implant system. Public materials describe the product as moving toward market launch; they do not establish that regulatory clearance or commercial deployment has been completed.
That open architecture could matter commercially. Spine-surgery systems sit inside established operating-room workflows, capital budgets and surgeon preferences. Compatibility with existing instruments can reduce the cost of adopting the platform, but Deneb still has to show that the integrated workflow is clinically dependable and easier to use than separate planning, navigation and treatment tools.
The company claims that IZAR can provide sub-millimetric accuracy and patient-specific ablation, but those remain company claims until validated in the settings where hospitals will use the system. The commercial milestone is therefore not only completing the hardware. Deneb must translate engineering performance into regulatory evidence, surgeon confidence, training and service support.
Strategic capital can shorten the route to market
The financing combines public investment, regional institutional backing and an industrial medical-device partner. SETT's €7.2m anchors the development in the Basque Country, where Deneb employs 22 people, while the unnamed US multinational may offer integration expertise and access to established commercial networks.
That partner mix addresses two different risks. Public capital can fund a long development cycle, while an industry partner can help Deneb understand procurement, platform integration and distribution. The advantage will depend on execution: a strategic investor creates a route into the market, but hospitals will still require evidence, support and a clear economic case before adopting another surgical system.
